Segui
Alba Brandes
Alba Brandes
Azienda USL-Irccs Bologna
Email verificata su ausl.bologna.it
Titolo
Citata da
Citata da
Anno
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp, WP Mason, MJ Van Den Bent, M Weller, B Fisher, ...
New England journal of medicine 352 (10), 987-996, 2005
225242005
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the …
R Stupp, ME Hegi, WP Mason, MJ Van Den Bent, MJB Taphoorn, ...
The lancet oncology 10 (5), 459-466, 2009
80972009
Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma
OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ...
New England Journal of Medicine 370 (8), 709-722, 2014
26542014
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
MJ Van Den Bent, AA Brandes, MJB Taphoorn, JM Kros, ...
Journal of clinical oncology 31 (3), 344-350, 2013
12872013
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre …
R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ...
The lancet oncology 15 (10), 1100-1108, 2014
10212014
Short-course radiation plus temozolomide in elderly patients with glioblastoma
JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ...
New England Journal of Medicine 376 (11), 1027-1037, 2017
10132017
European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of …
R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJ Taphoorn, ...
Lancet Oncol 10 (5), 459-466, 2009
10082009
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
AA Brandes, E Franceschi, A Tosoni, V Blatt, A Pession, G Tallini, ...
Journal of Clinical Oncology 26 (13), 2192-2197, 2008
9782008
Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial
DA Reardon, AA Brandes, A Omuro, P Mulholland, M Lim, A Wick, ...
JAMA oncology 6 (7), 1003-1010, 2020
9722020
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ...
The Lancet Oncology 18 (10), 1373-1385, 2017
9542017
Lomustine and bevacizumab in progressive glioblastoma
W Wick, T Gorlia, M Bendszus, M Taphoorn, F Sahm, I Harting, ...
New England Journal of Medicine 377 (20), 1954-1963, 2017
8972017
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and …
MJ van den Bent, AF Carpentier, AA Brandes, M Sanson, MJB Taphoorn, ...
Journal of Clinical Oncology 24 (18), 2715-2722, 2006
8572006
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
M Weller, R Stupp, G Reifenberger, AA Brandes, MJ Van Den Bent, ...
Nature Reviews Neurology 6 (1), 39-51, 2010
8502010
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
AJM Ferreri, M Reni, M Foppoli, M Martelli, GA Pangalis, M Frezzato, ...
The Lancet 374 (9700), 1512-1520, 2009
7132009
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ...
The Lancet Oncology 16 (15), e534-e542, 2015
6852015
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, ...
Journal of Clinical Oncology 27 (8), 1268, 2009
6382009
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3
T Gorlia, MJ van den Bent, ME Hegi, RO Mirimanoff, M Weller, ...
The lancet oncology 9 (1), 29-38, 2008
6382008
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
RO Mirimanoff, T Gorlia, W Mason, MJ Van den Bent, RD Kortmann, ...
J Clin Oncol 24 (16), 2563-2569, 2006
6272006
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
BG Baumert, ME Hegi, MJ van den Bent, A von Deimling, T Gorlia, ...
The Lancet Oncology 17 (11), 1521-1532, 2016
4892016
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for …
MJ Van den Bent, HJ Dubbink, Y Marie, AA Brandes, MJB Taphoorn, ...
Clinical Cancer Research 16 (5), 1597-1604, 2010
4782010
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20